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and after delivery which could complicate a mother’s ability to properly care for her newborn child. The
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with several gastrointestinal side effects. Alternative treatments include blood transfusions and intravenous
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corrected with iron therapy at some point during the trial regardless of the treatment method. Three studies
showed a significantly decreased amount of time to increase hemoglobin (Hb) levels in the women who
where treated with IV iron therapy. All of the studies showed a significant increase in ferritin levels in the IV
iron therapy group when compared to the oral iron group, with five of the six studies ending their studies with
significantly continued ferritin elevation in the IV iron group. The two studies that examined maternal quality-
of-life parameters reported non-significant improvements in the IV treatment group. Although both of these
studies also assessed maternal fatigue, only one study reported significant declines in physical and total fatigue.
Conclusion: Both ferric carboxymaltose and iron sucrose are safe and effective ways to treat postpartum iron
deficiency anemia. Both forms of IV iron are superior to oral ferrous sulfate as they require a shorter treatment
period, increase the likelihood of compliance, have no gastrointestinal side effects and rapidly replenish iron
stores.
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Abstract   
 
 
Background: Postpartum anemia can develop after delivery because of unforeseen 
medical problems during and after delivery which could complicate a mother’s ability to 
properly care for her newborn child.  The current treatment for postpartum anemia is oral 
iron supplementation but this treatment has been associated with several gastrointestinal 
side effects.  Alternative treatments include blood transfusions and intravenous (IV) iron 
therapy.  Since blood transfusions are very costly, IV iron treatments have become more 
popular.       
Objectives:  The objective of this review is to evaluate the hematological parameters and 
quality of life of women with postpartum anemia while being treated with IV iron sucrose 
or IV ferrous carboxymaltose compared to oral ferrous sulfate.  
Methods:  An exhaustive search of available medical literature was performed using 
three databases: MEDLINE, EMBASE and CINAHL.  All keywords were originally 
searched individually and then combined to refine the search.  The inclusion criteria 
consisted of randomized control trials (RCT) published in English after January 2000, 
which looked at hematologic parameters in postpartum anemic women being treated with 
either an oral iron supplement or IV iron therapy.  
Results:  Six RCTs involving 1140 women were reviewed.  Four of the studies showed 
that anemia was corrected with iron therapy at some point during the trial regardless of 
the treatment method.  Three studies showed a significantly decreased amount of time to 
increase hemoglobin (Hb) levels in the women who where treated with IV iron therapy.  
All of the studies showed a significant increase in ferritin levels in the IV iron therapy 
group when compared to the oral iron group, with five of the six studies ending their 
studies with significantly continued ferritin elevation in the IV iron group. The two 
studies that examined maternal quality-of-life parameters reported non-significant 
improvements in the IV treatment group.  Although both of these studies also assessed 
maternal fatigue, only one study reported significant declines in physical and total 
fatigue. 
Conclusion:  Both ferric carboxymaltose and iron sucrose are safe and effective ways to 
treat postpartum iron deficiency anemia.  Both forms of IV iron are superior to oral 
ferrous sulfate as they require a shorter treatment period, increase the likelihood of 
compliance, have no gastrointestinal side effects and rapidly replenish iron stores.   
Keywords:  postpartum anemia, intravenous iron, oral iron, ferric carboxymaltose, 
ferrous sulphate, anemia, iron deficiency. 
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Intravenous Iron Versus Oral Iron in the Treatment of Postpartum Iron Deficiency 
Anemia 
 
BACKGROUND 
Overview 
Childbirth should be a joyous event.  However, unforeseen medical problems 
such as postpartum hemorrhage or postpartum anemia can develop and make this time 
very difficult.  The physiological effects of pregnancy and blood loss at birth can 
exacerbate anemia.2   Blood loss from delivery is one of the most common causes of 
anemia.3  In the United States, about a quarter of the women who did not have anemia 
during pregnancy became anemic during the postpartum period.4  Depending on the 
severity of the blood loss, postpartum anemic women can be at a greater risk for 
morbidity and mortality.  Of the 515 000 maternal deaths worldwide in 1995, 20% were 
attributed to anemia.2   
The World Health Organization (WHO) defines iron deficiency anemia (IDA) as 
a hemoglobin (Hb) of less than 12 g/dL.2  The current gold standard for checking for IDA 
includes looking at both the Hb levels and the serum ferritin values.5  Ferritin is a protein 
that stores iron and releases iron as needed; it is the body’s regulator against iron 
deficiency.  By the time a patient is anemic they have already depleted their iron storage, 
as evidence by decreased levels of serum ferritin.  However ferritin can be falsely 
elevated because of a secondary inflammatory response.  Although ferritin alone cannot 
accurately predict IDA, it has been shown to have a possible association with depression 
and impairment of short-term memory.6,7 
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According to the National Pregnancy Nutrition Surveillance System, 29.8% of 
women who were not previously anemic during pregnancy become anemic after 
delivery.8  Consequences of postpartum IDA have been associated with fatigue, 
depression, cognitive dysfunction, stress, and anxiety.9  It can also interrupt mother-child 
bonding.  Studies have shown that infants of anemic mothers were developmentally 
delayed, possibly due to the fact that anemic mothers were significantly more “negative” 
towards their baby, engaged less in goal setting, and were less “responsive” than non-
anemic mothers.10   
Fatigue alone can be difficult to manage.  It can affect a person’s physical and 
mental health, their motivation to participate in everyday activities and even the desire to 
interact socially.  The everyday challenges of fatigue are significantly compounded after 
childbirth.  In addition to a new mother’s demanding tasks of caring for a child, 
postpartum fatigue can impact her postpartum maternal role attainment and may place her 
at greater risk for postpartum depression.11  Studies have shown that low Hb levels are 
significantly related to postpartum depression and postpartum fatigue.11 
Currently, the standard treatment for anemia is oral iron supplementation.  
However, this is limited by patient noncompliance and gastrointestinal symptoms such as 
nausea, vomiting, and diarrhea.12  Absorption of oral iron is influenced by the dosage, the 
patient’s iron storage, and the proximity of taking the medication relative to mealtime.  
Ideally, the supplement should be taken on an empty stomach as food can impair its 
absorption.13  This method of treatment is slow to take effect, often requiring several 
weeks for results to transpire.  
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Alternative treatment methods for anemia include intravenous (IV) iron therapy or 
blood transfusion.  Blood transfusions are very costly and come with great risk, 
contributing to the increased popularity of IV iron therapy treatment.5  Hematologic 
changes, like Hb and ferritin, are fairly rapid with IV iron therapy and have a positive 
effect on the body’s iron storage which is measured by the ferritin level.   
Intravenous iron administration with iron sucrose has been available for several 
years and is routinely used in a number of European countries to treat severe anemia.14  
Iron sucrose has an excellent safety record, unlike older IV formulations such as ferrous 
dextran, which has been associated with a significant risk of anaphylactoid reactions.15  
Intravenous iron sucrose can be administered as an infusion in small doses (about 200mg) 
over a 30-minute time period.16,15  A new IV iron preparation, ferric carboxymaltose, has 
been recently developed.  It provides rapid replacement of iron storage and can be 
administered in higher single doses of up to 1000mg during a minimum administration 
time of less than 15 minutes.1,12,16  Despite its advantages, this treatment option is not 
readily available as it is currently not FDA approved.   
Purpose of the Review 
Iron deficiency anemia is common in postpartum women and has been linked to 
postpartum fatigue and poor health outcomes.17  Thus, it is important to determine if there 
is a more effective way of treating postpartum anemia.  The primary objective of this 
systematic review is to determine whether using IV iron reduces the length of time 
required to resolve postpartum anemia.  The secondary objective is to look how the 
resulting postpartum anemia impacts maternal quality of life and mother-child relations.  
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This review compares treatment outcomes between the use of using either IV 
ferric carboxymaltose or IV iron sucrose in comparison with oral ferrous sulfate for the 
treatment of postpartum anemia.  The impact of the restoration of a mother’s iron storage 
on her quality of life will also be assessed. 
 
METHODS 
Search Strategy 
An exhaustive search of the current literature was performed using the research 
databases MEDLINE, EMBASE and CINAHL.  The keywords iron-deficiency anemia, 
postpartum anemia, ferric carboxymaltose, iron sucrose, and ferrous sulfate were used.  
Relevant studies were then reviewed and critiqued according to the inclusion and 
exclusion criteria discussed below. 
Inclusions/Exclusions 
The inclusion criteria for this review required all studies to be randomized 
controlled trials (RCT) published in English and after January of 2000.  The studies must 
evaluate hematological parameters in postpartum anemic women and how they respond 
to the treatment of postpartum anemia by either an oral iron therapy or an intravenous 
(IV) iron therapy.  All other studies were excluded if they did not meet these specific 
inclusion criteria. 
 
RESULTS 
After an extensive search of the literature, six randomized control trials (RCT) 
involving approximately 1140 women were included in this systematic review (See Table 
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1).1,12,14,16,18,19  Half of the studies compared treatment of intravenous (IV) ferric 
carboxymaltose to treatment with oral ferrous sulfate,1,12,16 while the other half compared 
treatment with IV iron sucrose to treatment with oral ferrous sulfate.14,18,19  All the studies 
used hematological parameters to report their results, including hemoglobin (Hb) and 
ferritin levels.  Two of the studies reported results on health-related quality of life 
variables (e.g. fatigue, physical function, mental health, body pain, etc).16,19  Treatment 
regimens for each study are outlined in Table 2.  
Breymann et al 
Breymann et al18 conducted a RCT of 60 postpartum anemic women in 
Switzerland from a single center, with a Hb of <10g/dL at 24-72 hours post delivery, to 
compare the efficacy between recombinant human erythropoietin plus IV iron sucrose 
(will not be discussed because lack of relevance to this review), versus IV iron sucrose 
alone, versus oral iron supplementation alone.  The hematologic parameters were 
measured on days 0, 4, 7, and 14.  At baseline, the groups did not differ characteristically 
or hematologically.  Three groups of 20 women were randomized using sealed envelops 
containing numbers allocated to one of three groups and started treatment within 48-72 
hours after delivery.  Baseline Hb and ferritin levels in the IV iron sucrose group and the 
oral iron supplementation group were 11.9g/dL and 12.2µg/L, respectively.  The study 
reported that all patients completed the study with 100% compliance to study treatments 
protocols.  The Hb levels increased steadily from baseline, but there was no statistical 
significance between the two groups.  The ferritin levels, however, significantly increased 
in the IV iron sucrose group to 162.3µg/L (p<0.01) by day 4.  The levels remained 
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elevated but fell slightly at the end of the trial, ending at 81.5µg/L (p< 0.01), compared to 
29.7µg/L and 21.7µg/L in the oral group on days 4 and 14, respectively.18 
Bhandal et al  
Bhandal et al14 conducted a RCT of 44 postpartum anemic women in the United 
Kingdom with a Hb of <9g/dL and a ferritin of <15µg/L at 24-48 hours post delivery, to 
evaluate various hematological parameters at days 0, 5, 14 and 40.  The study population 
was formed from a single center, where half of the women receiving IV iron sucrose 
(treatment group) and the other half receiving oral ferrous sulfate (control group).  The 
study was able to evaluate results from 43 women all of whom strictly complied with the 
treatment regimens.  The single exclusion occurred after randomization when one patient 
suffered a secondary postpartum hemorrhage that required a blood transfusion, excluding 
her from further participation in the study.  The two groups were characteristically and 
hematologically similar at baseline, with Hb levels of 7.3g/dL and 7.5g/dL and ferritin 
levels of 13.0µg/L and 11.0µg/L in the IV treatment group versus the oral control group, 
respectively.  The results indicated that both groups showed improvements in Hb levels 
throughout the study with higher levels in the IV group on days 5 and 14 (p<0.01).  The 
IV group had a mean increase in Hb level from baseline at day 5 of 2.5g/dL compared to 
the oral group of 0.7g/dL.   However, by day 40 there was no significant difference 
between the groups regarding the Hb level.  Ferritin levels in the IV treatment group 
showed a significant response by day 5, with levels at 48.0µg/L (p<0.01), and remained 
elevated for the duration of the study, ending at 42.2µg/L (p<0.05).  The group treated 
with oral iron supplementation had no increase in ferritin levels throughout the study.14    
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Westad et al  
Westad et al19 conducted a RCT of 129 postpartum anemic women in Norway 
from five obstetric departments, each with a Hb of ≥ 6.5g/dL and ≤ 8.5g/dL within 48 
hours after delivery, to compare the effect of IV iron sucrose to oral ferrous sulfate 
supplementation on hematological parameters and quality of life. The treatment group 
received IV iron sucrose and the control group received oral ferrous sulfate.  The women 
were followed up at 4, 8, and 12 weeks with blood sampling and assessments of quality 
of life parameters.  Both the Medical Outcomes Study Short Form 36 (SF-36) and the 
Fatigue Scale were utilized to assess quality of life parameter.  Of the 129 women who 
entered the trial, one dropped out prior to receiving any treatment and 35 patients either 
withdrew from the study at their own request, experienced an adverse event with study 
medication, or were lost to follow-up.  The study reported 95% compliance with the IV 
iron sucrose.  The compliance with oral treatment was less than 50% among both groups; 
this percentage took into account both groups because the IV treatment group started 
taking oral ferrous sulfate at the end of week 4.  The analysis of the results was based on 
an intent-to-treat (ITT) principle.  After 4 weeks, the mean Hb levels of both groups 
increased, however there was no significant difference between the groups.  The 
treatment group’s Hb level increased from 7.9g/dL to 11.9g/dL and the control group’s 
Hb level increased from 7.7g/dL to 12.3g/dL. Hemoglobin levels continued to increase 
from week 4 to week 8 with no significant difference between the groups, and then 
leveled off around week 8 for both groups.  The non-significant hemoglobin results 
included patients who received blood transfusions.  There was a significant increase in 
ferritin levels from the time of inclusion to week 4.  The ferritin level in the treatment 
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group increased from 26.0µg/L at baseline to 40.0µg/L at week 4 (p<0.001).  The oral 
control group showed very little change in ferritin levels throughout the study.  At week 8 
and 12, there were no significant differences between the groups with regard to the 
ferritin levels.19    
This study used the SF-36 to look at four main measures of a mother’s quality of 
life: the physical function score, the pain index, the vitality score, and the mental health 
score.  All scores improved throughout the study.  Although the changes were not 
significantly in favor of the treatment group throughout the study, at week 12 there was a 
significant difference in the pain index in favor of the treatment group.  The Fatigue 
Score comprised physical, mental, and total fatigue ratings.  In both groups the physical 
fatigue scores improved and the IV treatment group showed significantly greater 
improvements at weeks 4, 8 and 12 (p=0.02, p=0.02, p=0.03, respectively).  The mental 
fatigue score did not change between the groups.  Overall, the total fatigue score was 
significantly better in the treatment group after 4, 8, and 12 weeks (p=0.02 at each 
evaluation point).19    
A sub-analysis of 113 women was conducted to exclude patients who required 
blood transfusions.  This sub-analysis showed a significantly higher proportion of 
subjects treated with IV iron sucrose achieved a HB of at least 2g/dL (p=0.04).  Also, the 
treatment group showed significantly higher mean Hb levels at weeks 8 and 12 
(p=0.02).19    
Breymann et al 
Breymann et al12 randomized 349 postpartum anemic women from twenty centers 
in Romania, Russia, and Poland, with a Hb of ≤10.5g/dL, to compare the efficacy 
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between IV ferric carboxymaltose compared with oral ferrous sulfate.  This was a multi-
center, open-label RCT.  Patients were randomized according to a 2:1 ratio of ferric 
carboxymaltose to ferrous sulfate with stratification by country and severity of anemia.  
All patients received their first dose of medication within 7 days postpartum and then 
attended follow-up visits after 1, 2, 4 and, 12 weeks.  The groups did not differ at 
baseline in characteristics or hematologically.  Baseline Hb and ferritin levels in the IV 
treatment group and in the oral iron supplementation group were 9.67g/dL and 39.9µg/L, 
respectively.  The results reported were based on efficacy results from the pre-protocol 
analysis of 268 women which excluded women who had major protocol deviations or 
who discontinued the study prematurely because of patient request, adverse events, non-
compliance or loss to follow-up during the study.12   
The study also did an ITT analysis, which was not reported unless it differed from 
the per-protocol analysis because the results were similar.  There was a mean compliance 
of greater than 90% in the oral group and, with the exception of two patients, 100% 
compliance in the ferric carboxymaltose group.  Hemoglobin levels in both groups 
increased throughout the study but these increases were not significant at any time during 
the study.  Despite the non-significant results, the Hb levels of the IV treatment group did 
rise more rapidly by week 1 when compared to the oral control group.  Ferritin levels in 
the treatment group, however, increased significantly throughout the study.  At week 1 
the ferritin levels of the treatment group were significantly elevated at 568.2µg/L, while 
the control group showed only minimal increases at week two of 34.8µg/L.  By the end 
of the study there was still a significant elevation in the IV treatment group’s ferritin 
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level, compared to that of the oral control group (161.2µg/L versus 43.3µg/L, 
respectively).12 
Van Wyck et al 
Van Wyck et al16 conducted an open-label, phase III, randomized, active control 
non-inferiority, multi-center trial from February 8, 2005 to November 11, 2005, including 
361 postpartum anemic women from 43 sites (40 in the United States and 3 in Mexico) to 
determine the efficacy of rapid, large-dose IV ferric carboxymaltose to oral iron 
supplementation as evidenced by hematologic parameters and maternal health related 
quality of life assessments.  Patients were enrolled in the study within 10 days 
postpartum, with Hb of 10.0g/dL or less.  Subjects were excluded for any of the 
following reasons: previously demonstrated non-adherence to prescribed iron therapy, 
history of anemia due to causes other than iron deficiency anemia (IDA) or blood loss 
secondary to pregnancy or delivery, estimated vaginal bleeding more than 100mL in the 
24 hours prior to randomization, active severe infection, serum transferrin saturation of 
more than 50%, serum ferritin more than 500µg/L, serum creatinine more than 2.0mg/dL, 
serum transaminases more than 1.5 times upper limit of normal, evidence of untreated 
B12 or folate deficiency, received erythropoiesis-stimulating agents within 3 months 
before screening, history of myelosuppressive therapy, asthma under treatment, hepatitis, 
human immunodeficiency virus, or hematologic disorder other than iron deficiency.  
Nine women dropped out prior to initial dosing, therefore, 352 women were included in 
the safety population.  Twenty-five women in the safety population did not complete the 
study because of patient request, adverse events (pruritic rash, nausea, vomiting or 
diarrhea, non-drug-related depression and a non-drug-related death), loss to follow-up, 
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not meeting study criteria, or taking iron supplements not approved by the study protocol.  
The results were based on the ITT population (168 women in the IV treatment group and 
169 women in the oral control group) which consisted of all the safety patients except 15 
women who either did not have at least one Hb lab reading drawn after baseline, or 
patients who did not have a Hb of less than 11g/dL at baseline.  Among these patients, 
there was no significant difference at baseline between patients in either the treatment or 
the control group in demographics characteristics, iron status, or severity of anemia.  The 
study reported a 98% compliance rate in the treatment group compared to 83.8% in the 
oral group.16   
At the end of the study, there was no difference between the IV treatment group 
and the control group in the number of patients who achieved a rise in Hb 2.0g/dL or 
more within 42 days after baseline (96.4% versus 94.1%, p=0.443).  Patients assigned to 
the IV treatment group achieved Hb rise of 2.0 or more in less time than the oral control 
group (7 versus 14 days, p<0.001).  At each treatment interval after day 7, the proportion 
of patients who achieved a rise in Hb 3.0g/dL or more was greater in the IV treatment 
group.  The IV treatment group also had a greater proportion of patients who experienced 
a correction of anemia (achieving Hb more than 12.0g/dL) at each treatment interval and 
overall (90.5% versus 68.6%, p<0.001) (Figure 1).  The patients with the most severe 
anemia showed the greatest improvement in anemia correction when treated with IV 
ferric carboxymaltose.  The IV ferric carboxymaltose promptly increased serum ferritin 
levels, while the oral group showed no increase.  The groups showed significant 
differences at each study interval.16 
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The scores from the SF-36 at baseline for both groups were lower than expected 
for the physical component, and exceeded expectation for the mental portion but groups 
were similar at baseline.  Both groups experienced similar increases in SF-36 and 
decreases in Fatigue Linear Analog Scale Assessment scores.  However the difference 
between the groups was not significant at any point in the study.16 
Seid et al 
Seid et al1 conducted a multi-center, RCT, including an ITT population of 291 
postpartum anemic women in the United States from 28 centers from May 9, 2006 to 
December 27, 2006.  The purpose was to evaluate the efficacy, safety, and tolerability of 
IV ferric carboxymaltose (treatment group) when compared to the oral ferrous sulfate 
(control group).  Healthy postpartum anemic women who had delivered a child within 10 
days of starting the study with a Hb 10g/dL or less were included.  Excluded subjects had 
significant vaginal bleeding in the 24 hours prior to randomization, a history of anemia 
other than IDA or blood loss due to delivery, were undergoing treatment with 
myelosuppressive therapy or asthma therapy, had had recent blood transfusions, or 
erythropoietin within 3 months prior to screening.  Subjects were stratified according to 
average baseline Hb levels (8.0 or less, 8.1-9.0, 9.1-10.0g/dL), requirements for cesarean, 
and screening ferritin levels (25 or less or greater than 25µg/L) and then randomized.1   
The ITT population had two women discontinue prior to dosing (one from each 
group), leaving 289 women in the safety population.  The results presented were based on 
the modified intent to treat population (mITT) which included all subjects in the safety 
population who had at least one Hb reading after baseline.  The mITT population was 
based on 284 women with the exclusion of five women (four IV treatment group and one 
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oral control group) from the safety population.  The ITT population, which included these 
five women, was re-analyzed and the results were similar to the analysis of the mITT 
population.  The compliance rate of adhering to study protocol treatments was similar in 
both groups.  The investigators indicated there were no differences between treatment 
groups in the mITT, safety, evaluable, or ITT populations with regards to demographics 
or hematological parameters with baseline Hb levels of 8.91g/dL and 8.88g/dL and 
ferritin levels of 24.11µg/L and 23.91µg/L in the IV treatment versus oral groups, 
respectively.1   
The response of the mITT population that obtained a Hb greater than 12g/dL by 
the end of the study was significantly greater in the IV ferric carboxymaltose group when 
compared to the oral iron group (91.4% versus 66.7%, p<0.0001).  When looking at the 
subgroups (stratified by Hb levels) within this population, the subjects with the most 
severe anemia who received treatment showed the largest difference between the IV 
treatment versus oral group (78.9% versus 43.5%, p=0.0286) (See Figure 1).  The study 
also examined the percentage of subjects who had an increase in Hb ≥ 3g/dL at any time 
during the study; a Hb > 12g/dL on or before days 14, 28, and 42; an increase in Hb ≥ 
3g/dL on or before days 14, 28, and 42; and time to achieve a Hb greater than 12g/dL.  
All of these secondary endpoints significantly favored the IV treatment group.  The IV 
treatment group saw a significantly higher percentage of subjects who had an increase in 
Hb level of 3g/dL or greater (91.4% versus 64.6%, p<0.0001).  The results also 
significantly favored the IV treatment group when looking at length of time to achieve 
endpoints. a median time to achieve a Hb greater than 12g/dL (14 versus 27 day, 
p=0.0002) and the median time to achieve an increase in Hb 3g/dL or greater (15 versus 
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28 days, p<0.0001).  Similarly favorable, the ferritin levels of the IV treatment group 
remained replenished when compared to the control group (238µg/L versus 21µg/L, 
p<0.0001).  Finally, there was a greater significance noted in the percentage of IV 
treatment group subjects who had a sustained Hb greater than 12g/dL at the end of the 
study compared to the control group (85.4% versus 58.0%, p<0.0001).1 
 
DISCUSSION 
For many pregnant women, postpartum iron deficiency anemia (IDA) is 
inevitable and can be detrimental to the mother and newborn.  After childbirth, it is 
normal for hemoglobin (Hb) levels to drop during the first 24 hours due to the loss of 
blood during delivery, however the Hb level should rise over the next two to five days 
and return to normal by the seventh day after delivery.20  If the Hb level does not rise 
adequately, postpartum IDA may become a serious problem and may create other 
problems for the new mother.  Studies have shown postpartum women being treated with 
oral iron when compared to a placebo or non-treatment groups,21 show more rapid Hb 
increases and correction of anemia with minimal replenishment of iron storage.21,22   
Postpartum fatigue and a mother’s declining health have been linked to IDA.17  In 
addition to fatigue, symptoms of anemia include: inability to concentrate, general apathy, 
and irritability; all of which can seriously impact a new mother’s quality of life.17  Not 
surprisingly, all of these factors appear on Beck and Indman’s list of presentations of 
postpartum depression.23  Studies have shown that treating postpartum IDA with oral iron 
supplements can improve a mother’s depression and stress scales.9  Therefore, in order to 
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preclude the onset of postpartum depression, it is extremely important to determine a 
treatment that reduces recovery time for women with postpartum anemia.  
The primary purpose of this systematic review is to determine whether IV iron is 
a more effective treatment when compared to oral iron therapy in reducing the length of 
time required to correct postpartum anemia.  At first glance, the results of this review 
appeared to be inconclusive as half of the studies reported significant Hb changes in the 
IV treatment groups at some point during the study,14,1,16 while the other half reported 
non-significant results regarding Hb changes.12,18,19  Although, after re-examining each 
studies inclusion and exclusion criterion, five of the six studies excluded patients 
requiring blood transfusions,1,12,14,16,18 while one of the studies19 with non-significant 
results included these patients.  Fortunately, the latter study did a sub-analysis, excluding 
patients who required blood transfusions, thus giving all six studies a common ground to 
make a viable conclusion about increasing Hb.  The results of the sub-analysis in Westad 
et al19 revealed a significant change in Hb of at least 2.0g/dL by week four in the 
treatment group and there was a significant increase in the mean Hb levels of the 
treatment group at weeks eight and twelve when compared to the oral group.  Therefore, 
four studies showed significant improvements in Hb levels, leaving only two studies with 
non-significant results, which were conducted by the same author.12,18   
Each of the studies except Bhandal et al14 and Breymann et al,18 reported a higher 
percentage of patients who achieved a Hb of greater than 12g/dL at some point during the 
study using either IV ferric carboxymaltose or IV iron sucrose.  However only the studies 
done by Seid et al,1 Van Wyck et al,16 and Westad et al19 were statistically significant.  
Although the Bhandal et al14 study participants did not reach a Hb of 12g/dL, the mean 
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Hb baseline was 7.4g/dL.  Despite the low baseline Hb, the IV group was able to achieve 
a significant mean Hb increase of 2.5g/dL in the IV group by day five and a statistically 
significant mean Hb increase of 1.2g/dL in the IV group by day 14.  Seid et al1 also 
reported the time to achieve anemia correction was significantly less in the IV treatment 
group, 14 versus 27 days, while improvements in Hb levels continued for the remainder 
of the study.   
All the studies reported that the IV treatment groups showed a significant 
elevation in ferritin levels at some point during the testing period.  Five of the six studies 
reported that the ferritin levels remained significantly elevated in the IV treatment groups 
compared to the oral groups at the termination of each study.1,12,14,16,18  Thus, the 
participants’ iron storage had been replenished more quickly than the participants being 
treated with oral ferrous sulfate.   
Iron status in women of reproductive age significantly affects cognitive 
performance.24  This study also observed association between changes in ferritin and 
changes in performance, strongly suggesting the brain iron deficiency is causally related 
to these changes in cognitive performance.24  The two studies examined how postpartum 
anemia affects a mother’s quality of life with both studies showing improvements in both 
the IV and oral groups with regards to all aspects of the Medical Outcomes Study Short 
Form 36 (SF-36), although neither was significant.  Both studies showed reduction in 
fatigue; Westad et al19 study showed significant improvement in total fatigue at four, 
eight and twelve weeks in women being treated with IV iron sucrose, while Van Wyck et 
al16 showed no significance between the groups.  Since the two studies that looked at 
maternal quality of life parameters did not have significant results, the actual assessment 
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tool used to quantify these parameters could have played a role in the lack of 
significance.   
Compliance in each study was, for the most part, fairly high.  In the clinical 
setting it may be difficult to get the same rate of compliance for oral iron therapy as the 
studies observed because the subjects were willing participants and were given 
encouragement and reminders by researches to comply with treatment regimens.  
Study Limitations 
 Various limitations plagued the reviewed studies.  One limitation is that none of 
the studies were blinded, thus possibly opening the door for non-study clinicians to be 
more prone to ordering patients blood transfusions if they were not responding to study 
treatments, thus requiring these subjects to be excluded.  Also, the studies done by 
Bhandal et al14 and Breymann et al18 looked at very small populations of less than 100 
subjects, and Breymann et al18 only studied the participants for a two week time period.  
Another limitation concerns the process of including or excluding certain individual 
subjects from the study results.  For example, Westad et al19 had non-significant results 
when including patients who required blood transfusions, yet had significant results when 
looking at only patients who did not require blood transfusions.   
With the exception of the Seid et al1 study, which used the methods from the Van 
Wyck et al,16 there was little to no uniformity in how the studies were carried out.  
Treatment administration varied widely among studies.  Some studies prescribed iron 
twice daily14,12,18,19  while others prescribed thrice daily1,16 at various dosages.  The 
studies treating patients with IV iron sucrose also were also inconsistent.  The total 
treatment dosage in these studies ranged from 400mg to 800mg among the treatment 
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groups.  As none of the studies have looked at standard dosage of iron therapy, this would 
be an excellent topic of further research.  Another limitation concerned the times at which 
the studies drew labs to make their conclusions.  For example, Bhandal et al14 drew labs 
five days after baseline, while Westad et al19 had the initial hematological parameters 
drawn at four weeks after baseline.  The shorter time interval increases the ability of the 
researchers to collect important data which could indicate if and when Hb levels returned 
to normal and how the treatment affected the acute anemia.   
  
CONCLUSION 
Both ferric carboxymaltose and iron sucrose are safe and effective ways to treat 
postpartum iron deficiency anemia.  Both forms of intravenous (IV) iron have shorter 
treatment periods, increased likelihood of compliance, a lack of gastrointestinal side 
effects, and rapid replenishment of iron stores, making them superior to oral ferrous 
sulfate.  The efficacy of each of the IV iron treatments, iron sucrose and ferric 
carboxymaltose, have yet to be compared.  Future research in this direction would be 
helpful to guide practitioners in treating their patients with the safest, most effective 
therapy.  Furthermore, the relationship between depleted iron stores and fatigue needs to 
be explored.25  Currently, there are very few studies which examine how anemia affects 
maternal quality of life parameters.  Future research should focus on developing a more 
effective treatment.  An assessment also needs to be made as to how maternal quality of 
life and postpartum fatigue affect mother-child interaction and child development.   
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Table 1: Summary of Reviewed Articles    
Author/  
Title/ 
Journal 
Yr. 
published 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study 
type 
Validity 
(Jadad 
score) 
Bhandal et 
al14 
2006 43 Anemic women 
(Hb <9g/dL) 24-48 
hrs post delivery  
IV ferrous 
sucrose 
Oral ferrous 
sulfate 
Hb, ferritin, transferring 
saturation, red cell indices, 
transfusions, tolerability to 
mothers and breast milk sub-
study.  
RCT 3 
Breymann 
et al18 
2000 60 Anemic women 
(Hb <10g/dL) 24-
72 h after delivery 
IV ferrous 
sucrose 
Oral ferrous 
sulfate 
Hb, hematocrit, erythropoietin, 
ferritin, C-Reactive protein 
RCT 3 
Breymann 
et al12 
2008 268 Anemic 
women (Hb 
≤105g/L) ≤7 days 
postpartum 
IV Ferric 
Carboxymaltose 
Oral ferrous 
sulfate 
Hb, hematocrit, red cell indices, 
ferritin and serum iron levels 
measured on baseline, weeks 2, 
4, and 12. 
RCT 3 
Seid et al1 2008 289 Anemic 
women (Hb 
≤10g/dL) ≤10 days 
postpartum 
IV Ferric 
Carboxymaltose 
Oral ferrous 
sulfate 
Correction of anemia, achieving 
Hb >12g/dL, achieving increase 
in Hb ≥3g/dL, changes in 
ferritin and serum transferrin 
saturation 
RCT 3 
Van Wyck 
et al16 
2007 352 Anemic 
women (Hb 
≤10g/dL) ≤10 days 
postpartum 
IV Ferric 
Carboxymaltose 
Oral ferrous 
sulfate 
Correction of anemia RCT 3 
Westad et 
al19 
2008 128 Postpartum 
women (Hb 
≥6.5g/100ml and 
≤8.5g/100ml) ≤48 
post delivery 
IV ferrous 
sucrose 
Oral ferrous 
sulfate 
Hb, ferritin and quality of life 
assessed w/ the Medical 
Outcomes Study Short Form 36 
and the Fatigue Scale 
RCT 3 
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Table 2: Study Approaches for Dosing Iron Supplementation  
 Intravenous Iron Therapy Oral Iron Therapy 
 Ferric Carboxymaltose Iron Sucrose Ferrous sulfate 
Breymann  
et al, 200018 
Not given 200mg administered on day 1-4.  
From day 5 to the end of the study 
(day 14) subjects were given oral 
iron supplementation of 80mg iron 
sulfate plus folic acid (0.35mg) 
taken twice daily, one hour before 
meals on an empty stomach  
80mg iron sulfate plus folic 
acid (0.35mg) taken twice 
daily, one hour before meals 
on an empty stomach x 14 
days 
Bhandal et 
al, 200614 
Not given 200mg administered in an infusion 
of 250mL of 0.9% sodium chloride 
for more than 30 minutes on days 2 
and 4 
200mg ferrous sulfate, BID 
x 6 weeks, subjects 
instructed to take 
supplement with meal 
Westad et al, 
200819 
Not given 200mg administered on day 1-3.  At 
the start of week 5, subjects were 
given oral iron supplementation of 
100mg ferrous sulfate twice daily 
taken twice daily. 
100mg ferrous sulfate, BID 
x 12 weeks. 
Breymann et 
al, 200812 
Maximum1000mg over 15 minutes 
(15mg iron/kg body weight if body 
weight <66kg) on day 1, subsequent 
dose at 1 week intervals until 
patient’s calculated total iron 
requirement  was reached (up to 3 
weekly infusions); Calculation for 
total iron requirement was done by 
using a modified Ganzoni26 formula 
Not given 100 mg BID x 12 weeks 
Seid et al,  
20081 
Maximum 1000mg over 15 minutes 
(15mg iron/kg body weight if body 
weight <66kg) on day 1, subsequent 
dose at 1 week intervals until 
patient’s calculated total iron 
requirement  was reached (up to 3 
weekly infusions); Maximum total 
dosage of 2500mg; Calculation for 
total iron requirement was done by 
using a modified Ganzoni26 formula 
Not given 325mg tablets TID for 6 
weeks 
Van Wyck et 
al, 200716 
Maximum 1000mg over 15 minutes 
(15mg iron/kg body weight if body 
weight <66kg) on day 1, subsequent 
dose at 1 week intervals until 
patient’s calculated total iron 
requirement  was reached (up to 3 
weekly infusions); Maximum total 
dosage of 2500mg; Calculation for 
total iron requirement was done by 
using a modified Ganzoni26 formula 
Not given 325mg tablets TID with 
instructions to take 1 tablet 
by mouth three times daily 
with 8 ounces of water, one 
hour before meals on day 0 
to 42. 
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Figure 1:  Subjects Achieving Correction of Anemia by Baseline Hb in Seid et al1 Research.   
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severity of anemia at baseline.  The difference in efficacy between ferric carboxymaltose 
and ferrous sulfate was greater in patients with the most severe anemia 
*P = 0.0286, ** P = 0.0008, † P = 0.0054, †† P = 0.1000. n/N, number of subjects who 
achieved a Hb greater than 12g/dL/number of subjects in the treatment group.1  
 
 
 
 
 
 
 
